Plasmodium, the causative agent of malaria, has many morphologically and functionally distinct developmental stages.
Laveran first described pigmented bodies in humans to define a protozoan as the aetiologic agent of malaria.
The causative agent of malaria, Plasmodium falciparum posses a single aquaglyceroporin (PfAQP) which represents a potential drug target for treatment of the disease.
Plasmodium falciparum, the causative agent of malaria, is sensitive to oxidative stress and therefore the family of antioxidant enzymes, peroxiredoxins (Prxs) represent a target for antimalarial drug design.
Thenceforward many researchers tested DFMO and also other polyamine synthesis inhibitors against different parasites among them the causative agent of malaria Plasmodium.
In recent years, groundbreaking advances have been made in understanding the biology of and immune mechanisms against the Plasmodium spp. parasite, the causative agent of malaria.
Novel imidazo[4,5-c]quinolin-2-ones were synthesized and evaluated in asexual blood stage and late stage gametocyte assays of Plasmodium falciparum, a major causative agent of malaria.
The D2 fribronectin-binding domain from Staphylococcus aureus (Georgianna and Mayfield [2012]) and the transmission blocking Pfs25 antigen from Plasmodium falciparum, the causative agent of malaria (Gregory et al. [2013]), have been shown to elicit systemic and mucosal responses when fed to mice in a lyophilized powder of algae.
Plasmodium, the etiologic agent of malaria, is a unicellular facultative intracellular parasite of the phylum Apicomplexa.
Plasmodium is the causative agent of malaria, and P. falciparum, one of four species that infects humans, is the most virulent.
